Goldman Sachs
PALI icon

Goldman Sachs’s Palisade Bio PALI Stock Holding History

Goldman Sachs’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Hold
0
– -$555K – 7438
2015
Q2 		– Hold
0
– – – 5096

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Goldman Sachs's PALI Position: Q2 2026 in Review

Goldman Sachs reduced its Palisade Bio (PALI) stake by 33% in Q2 2026, selling an estimated $3.53M and leaving 3,578,020 shares worth $7.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3515.

Goldman Sachs first reported a position in PALI in Q2 2015 and has held it in 4 quarters since. The position peaked at $9.4M in Q1 2026. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Goldman Sachs held 3,578,020 shares of Palisade Bio worth $7.48M as of Q2 2026.
  • Goldman Sachs sold 1,795,931 Palisade Bio shares in Q2 2026, an estimated $3.53M.
  • Palisade Bio made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3515 holding.
  • Goldman Sachs first reported a position in Palisade Bio in Q2 2015 and has held it in 4 quarters since.
  • Goldman Sachs's Palisade Bio position peaked at $9.4M in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.